Literature DB >> 19297157

Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.

Takeshi Yamamoto1, Norio Shibata, Daisuke Sukeguchi, Masayuki Takashima, Shuichi Nakamura, Takeshi Toru, Nozomu Matsunaga, Hideaki Hara, Motohiro Tanaka, Tohru Obata, Takuma Sasaki.   

Abstract

The first asymmetric synthesis of (S)- and (R)-5-hydroxythalidomides, one of thalidomide's major metabolites, was achieved using HMDS/ZnBr(2)-induced imidation as a key reaction. 5-Hydroxythalidomide was found to be configurationally more stable than thalidomide at physiological pH. Stereochemical biological effects of thalidomide and 5-hydroxythalidomide on anti-angiogenesis and antitumor activities were also investigated using racemic and pure enantiomers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297157     DOI: 10.1016/j.bmcl.2009.02.108

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

2.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

3.  Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.

Authors:  Makiko Shimizu; Hiroshi Suemizu; Marina Mitsui; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Xenobiotica       Date:  2016-11-16       Impact factor: 1.908

4.  The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.

Authors:  Tasaduq H Wani; Anindita Chakrabarty; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich; Goutam Chowdhury
Journal:  Chem Res Toxicol       Date:  2017-08-02       Impact factor: 3.739

5.  Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Authors:  Norie Murayama; Rinie van Beuningen; Hiroshi Suemizu; Christiane Guguen Guillouzo; Norio Shibata; Kanako Yajima; Masahiro Utoh; Makiko Shimizu; Christophe Chesné; Masato Nakamura; F Peter Guengerich; René Houtman; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2014-02-05       Impact factor: 3.739

Review 6.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

7.  Human iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arrays.

Authors:  David G Belair; Michael P Schwartz; Thomas Knudsen; William L Murphy
Journal:  Acta Biomater       Date:  2016-05-13       Impact factor: 8.947

8.  Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications.

Authors:  Mayaka Maeno; Etsuko Tokunaga; Takeshi Yamamoto; Toshiya Suzuki; Yoshiyuki Ogino; Emi Ito; Motoo Shiro; Toru Asahi; Norio Shibata
Journal:  Chem Sci       Date:  2014-10-30       Impact factor: 9.825

9.  Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.

Authors:  Hirotake Furihata; Satoshi Yamanaka; Toshiaki Honda; Yumiko Miyauchi; Atsuko Asano; Norio Shibata; Masaru Tanokura; Tatsuya Sawasaki; Takuya Miyakawa
Journal:  Nat Commun       Date:  2020-09-14       Impact factor: 14.919

10.  Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers.

Authors:  Etsuko Tokunaga; Takeshi Yamamoto; Emi Ito; Norio Shibata
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.